| Literature DB >> 8529502 |
Abstract
Extrapancreatic action of sulfonylurea (SU) drugs were extensively summarized. Hypoglycemic SU drugs stimulate glycolytic pathway and inhibit gluconeogenic pathway in the liver through regulating key enzymes such as the bifunctional enzyme PFK2/F-2,6-P2ase and PEPCK. It is possible that SUs improve the primary defects in NIDDM through both pancreatic and extrapancreatic actions.Entities:
Mesh：
Substances：
Year: 1995 PMID： 8529502 DOI： 10.1016/0168-8227(95)01078-r
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN： 0168-8227 Impact factor: 5.602